Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + raltitrexed + tislelizumab + surufatinib + TAE
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial, Intravenous, Oral
01
Overview
HAIC + TAE sequential therapy combined with tislelizumab and surufatinib is an investigational multi-modal treatment regimen for unresectable intrahepatic cholangiocarcinoma (iCCA). The regimen, currently being evaluated in the Phase II REACH-01 trial (NCT06239532) by Qilu Hospital of Shandong University, combines hepatic artery infusion chemotherapy (HAIC) using oxaliplatin and raltitrexed with transcatheter arterial embolization (TAE). This locoregional approach is supplemented by systemic therapy consisting of tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody, and surufatinib, a small molecule inhibitor of VEGFR 1/2/3, FGFR1, and CSF-1R. The combination aims to leverage the synergistic effects of local tumor destruction, anti-angiogenesis, and immune checkpoint inhibition to improve outcomes in patients with advanced biliary tract cancers.
- Other names
- HAIC+TAE + Tislelizumab + SurufatinibHAIC sequential TAE combined with Tislelizumab and Surufatinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on oxaliplatin + raltitrexed + tislelizumab + surufatinib + TAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + raltitrexed + tislelizumab + surufatinib + TAE.